RxDoctor Payments Data

Janine Doneza, MD

Gynecology · Hilo, HINPI 1003129420

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Applied Medical Resources Corporation at 27.4% of the total. Reporting peaked in 2022 at $894 and has fallen 81.7% since, to $164 in 2025.

$2,521in general payments, 2019–2025

Across 34 payments — averaging $74.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Applied Medical Resources Corporation$691
  • Davol Inc.$509
  • Hologic Sales And Service, LLC$333
  • Medical Device Business Services, Inc.$325
  • Aspira Women's Health Inc$208
  • Astellas Pharma US Inc$145
  • plus $309 from 6 others

What the payments were for

  • Travel & lodging$97539%
  • Food & beverage$1,22148%
  • Education$32513%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecology providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$6,589
Medicare patients
11
Services billed
11

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron19$17,180
Tolterodine Tartrate ErTolterodine Tartrate11$1,913
Estradiol32$1,653
Methenamine Hippurate17$1,146
NitrofurantoinNitrofurantoin Macrocrystal15$546
Oxybutynin Chloride28$538
Nystatin34$410
Clobetasol Propionate13$394
Metronidazole31$386
Fluconazole34$121
Ibuprofen14$42
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$34
Misoprostol16$27
Tramadol Hcl14$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$145$17,18019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecology providers in Hawaiion file to place this against a meaningful peer group, so we don't.

Other gynecology in Hilo

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →